Valuation
- Market cap
- 4,212,835,000
- Revenue TTM
- $75,130,000
- Net income TTM
- $-146,410,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -194.88%
- Debt to equity
- 0.00
Trading
- Volume
- 4,074,000
- Avg volume
- 7,036,940
- Day's range
- $13.21 – $13.88
- Shares out
- 306,611,000
- Stochastic %K
- 62%
- Beta
- 1.41
- Analysts
- Strong Sell
- Price target
- $16.70
Company profile
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-medi...
Show more
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 604 559 9005
- Website
- https://www.abcellera.com
- Address
- 150 W 4th Avenue, Vancouver, Canada
Latest news
No headlines yet.
Stocktwits
Rastafari
Oct 5, 8:23 PM
$ABCL interesting news!
https://www.bbc.com/news/articles/cv5yn3nwp5n5o
Carl may get a call!
0 replies
kingGstark
Oct 5, 5:35 PM
$ABCL buying a bunch of this preparing the rebounce to 15, lets gooo
1 replies
BobFordTrades
Oct 5, 1:33 PM
$ABCL Momentum screens don't read 8-Ks. AbCellera priced a ~
$200M primary offering on Aug 12 (8-K filed Aug 13). Three rounds of AI-assisted review of my watchlist missed it; a full rerun from the filings caught it. Check the filing before you chase. No position.
0 replies
Merlintrader
Oct 4, 11:31 PM
AbCellera (
$ABCL): Q3 Results on November 9 and the Next Clinical Tests
Explore the company, catalysts and risks in our research hub.
https://www.merlintrader.com/abcellera-biologics-stock-hub/
Rastafari
Oct 4, 6:31 PM
$ABCL This job description signals that ABCL is positioning itself to move beyond drug discovery into late-stage development and commercialization. The emphasis on BLA submissions, approval and commercial launch suggests management is building the capabilities to capture much more of the value from its own pipeline—particularly assets like ABCL635 and ABCL575. To me, this is another indication that ABCL is evolving from a discovery platform into a fully integrated biotech, which could also make the company significantly more attractive to Big Pharma.
https://share.google/S5bIr6UG6EZbVu7w0
0 replies
Bastox
Oct 3, 2:53 AM
$ABCL Earnings call:
VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) will announce its third quarter 2026 financial results on Monday, November 9, 2026, and hold an earnings conference call at 3:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.1/1 · top ↑
A live audio webcast of the earnings conference may be accessed through a link that will be posted on AbCellera’s Investor Relations website. A replay will be available through the same link following the conference call.
0 replies
